Roche (OTCMKTS:RHHBY) Downgraded to “Sell” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft lowered shares of Roche (OTCMKTS:RHHBY) from a hold rating to a sell rating in a research note issued to investors on Friday, Marketbeat Ratings reports.

A number of other brokerages also recently commented on RHHBY. The Goldman Sachs Group assumed coverage on shares of Roche in a research note on Thursday, May 30th. They issued a sell rating on the stock. Bank of America raised shares of Roche from a neutral rating to a buy rating in a report on Friday. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Hold.

Roche Stock Performance

Shares of OTCMKTS RHHBY opened at $39.21 on Friday. Roche has a 1 year low of $29.20 and a 1 year high of $42.43. The firm’s 50 day moving average price is $39.69 and its 200 day moving average price is $34.89. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.04 and a current ratio of 1.35.

Institutional Trading of Roche

A number of hedge funds have recently bought and sold shares of RHHBY. Saratoga Research & Investment Management raised its stake in shares of Roche by 6.9% in the 1st quarter. Saratoga Research & Investment Management now owns 2,458,918 shares of the company’s stock valued at $78,489,000 after buying an additional 158,482 shares in the last quarter. Cardinal Capital Management Inc. acquired a new stake in Roche in the 2nd quarter valued at about $16,860,000. OLD National Bancorp IN increased its position in Roche by 3.2% in the 2nd quarter. OLD National Bancorp IN now owns 265,242 shares of the company’s stock valued at $9,206,000 after acquiring an additional 8,146 shares in the last quarter. Altrius Capital Management Inc increased its position in Roche by 6.0% in the 2nd quarter. Altrius Capital Management Inc now owns 224,804 shares of the company’s stock valued at $7,794,000 after acquiring an additional 12,646 shares in the last quarter. Finally, Meritage Portfolio Management boosted its stake in shares of Roche by 186.9% in the 1st quarter. Meritage Portfolio Management now owns 174,714 shares of the company’s stock valued at $5,577,000 after purchasing an additional 113,823 shares during the last quarter.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.